TY - JOUR
TI - Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis
AU - Kallieri, M.
AU - Zervas, E.
AU - Katsoulis, K.
AU - Fouka, E.
AU - Porpodis, K.
AU - Samitas, K.
AU - Papaioannou, A.I.
AU - Kipourou, M.
AU - Gaki, E.
AU - Vittorakis, S.
AU - Markatos, M.
AU - Dimakou, K.
AU - Ampelioti, S.
AU - Koukidou, S.
AU - Makris, M.
AU - Ntakoula, M.
AU - Mitrova, M.H.
AU - Glynos, K.
AU - Antoniou, K.M.
AU - Gaga, M.
AU - Tzanakis, N.
AU - Markopoulou, K.
AU - Papakosta, D.
AU - Bakakos, P.
AU - Loukides, S.
JO - International Archives of Allergy and Immunology
PY - 2020
VL - 181
TODO - 8
SP - 613-617
PB - S Karger AG
SN - 1018-2438, 1423-0097
TODO - 10.1159/000508559
TODO - mepolizumab;  prednisolone;  antiasthmatic agent;  corticosteroid;  mepolizumab;  monoclonal antibody, adult;  Article;  asthma;  Asthma Control Test;  controlled clinical trial;  controlled study;  corticosteroid therapy;  disease exacerbation;  disease severity;  drug safety;  eosinophil count;  eosinophilic asthma;  eosinophilic asthma;  female;  follow up;  forced expiratory volume;  forced vital capacity;  Greece;  human;  immunotherapy;  maintenance drug dose;  major clinical study;  male;  middle aged;  multicenter study;  observational study;  priority journal;  prospective study;  respiratory airflow;  unspecified side effect;  aged;  asthma;  clinical trial;  hospital;  immunology;  Loeffler pneumonia;  lung function test;  treatment outcome, Adrenal Cortex Hormones;  Aged;  Allergy and Immunology;  Anti-Asthmatic Agents;  Antibodies, Monoclonal, Humanized;  Asthma;  Disease Progression;  Female;  Follow-Up Studies;  Greece;  Hospitals, Special;  Humans;  Male;  Middle Aged;  Prospective Studies;  Pulmonary Eosinophilia;  Respiratory Function Tests;  Treatment Outcome
TODO - Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab. Methods: This study is a prospective multicenter, noninterventional 2-year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3 ± 2.3 to 1.3 ± 1.8; p < 0.0001. Forty-two patients received maintenance dose of oral corticosteroids (OCS) at baseline. From these patients at the end of 1 year of therapy with mepolizumab, 17 patients (40%) had achieved OCS discontinuation. A reduction in the median dose of OCS was also achieved. After 1 year of treatment with mepolizumab, the asthma control test score significantly increased from 16.3 ± 3.7 to 21.2 ± 3.8 (p < 0.0001). This marked clinical improvement was paralleled by a significant reduction of blood eosinophil count. All patients showed a considerable improvement of airflow limitation. In respect to adverse events of treatment with mepolizumab, 19 patients (27%) were recorded to have at least one such occurrence during their 1-year treatment. Conclusions: We have shown that in patients with severe eosinophilic asthma, 1 year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of OCS, and improvements of asthma control and lung function. © 2020
ER -